ChemicalBook > CAS DataBase List > Etrolizumab

Etrolizumab

Product Name
Etrolizumab
CAS No.
1044758-60-2
Chemical Name
Etrolizumab
Synonyms
Etrolizumab;rhuMAb Beta7;Etrolizumab (anti-α4β7);Research Grade Etrolizumab;Research Grade Etrolizumab(DHC98803)
CBNumber
CB58080827
Formula Weight
0
MOL File
Mol file
More
Less

Etrolizumab Property

storage temp. 
Store at -20°C
form 
Liquid
color 
Colorless to light yellow
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

Etrolizumab Chemical Properties,Usage,Production

Uses

Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with Ki values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD)[1][2].

in vivo

Etrolizumab (rhuMAb Beta7; 5 mg/kg; i.v.; once; normal female BALB/c mice) decreases β7 integrins on T lymphocytes[2].
Etrolizumab (200 μg (100 μL); i.p.; once) inhibits lymphocyte homing in the CD45RBhigh T cell-reconstituted SCID mouse model of colitis[2].

Animal Model:Normal female BALB/c mice (17-21 g)[2]
Dosage:5 mg/kg
Administration:Intravenous injection; once
Result:Had 98.3% of intraepithelial CD8+ T-cell β7 integrin receptors and 90.0% of intraepithelial CD4+ T-cell β7 integrin receptors after 24 h.
Animal Model:SCID mouse model of colitis[2]
Dosage:200 μg (100 μL)
Administration:Intraperitoneal injection; once
Result:Blocked lymphocyte recruitment and homing to the inflamed colon.

IC 50

α4β7; αEβ7

References

[1] Tang MT, et, al. Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel disease. Aliment Pharmacol Ther. 2018 Jun;47(11):1440-1452. DOI:10.1111/apt.14631
[2] Stefanich EG, et, al. A humanized monoclonal antibody targeting the β7 integrin selectively blocks intestinal homing of T lymphocytes. Br J Pharmacol. 2011 Apr;162(8):1855-70. DOI:10.1111/j.1476-5381.2011.01205.x

Etrolizumab Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Etrolizumab Suppliers

Shanghai YuanYe Biotechnology Co., Ltd.
Tel
021-61312847; 18021002903
Fax
QQ:3008007432
Email
3008007409@qq.com
Country
China
ProdList
71826
Advantage
60
ShangHai Biochempartner Co.,Ltd
Tel
177-54423994 17754423994
Fax
QQ:2853530913
Email
2853530910@QQ.com
Country
China
ProdList
8000
Advantage
62
Beijing Solarbio Science & Tecnology Co., Ltd.
Tel
010-50973130 18101056239
Email
3193328036@qq.com
Country
China
ProdList
29759
Advantage
68
Guangzhou Hongyuan Chemical Co.,Ltd
Tel
15817493340
Email
981810490@qq.com
Country
China
ProdList
1566
Advantage
58
Wuhan Chemstan Biotechnology Co., Ltd.
Tel
027-65317797 15926423062
Fax
QQ:422450190
Email
422450190@qq.com
Country
China
ProdList
10308
Advantage
58
Guangdong wengjiang Chemical Reagent Co., Ltd.
Tel
0751-2815987 13927875076
Fax
0751-2828607
Email
3007432263@qq.com
Country
China
ProdList
9963
Advantage
58
TargetMol Chemicals Inc.
Tel
4008200310
Email
marketing@tsbiochem.com
Country
China
ProdList
24961
Advantage
58
Biolab Reagents
Tel
027-65279366 18108604356
Email
products@biolabreagent.com
Country
China
ProdList
9868
Advantage
58
Wuhan Jingkangen Biomedical Technology Co., Ltd
Tel
13720134139 086-15871494362 13720134139
Email
orders@jknbiochem.com
Country
China
ProdList
6762
Advantage
58
Shanghai Yifei Biotechnology Co. , Ltd.
Tel
021-65675885 18964387627
Email
customer_service@efebio.com
Country
China
ProdList
11973
Advantage
58

1044758-60-2, EtrolizumabRelated Search:


  • Etrolizumab
  • Research Grade Etrolizumab(DHC98803)
  • rhuMAb Beta7
  • Etrolizumab (anti-α4β7)
  • Research Grade Etrolizumab
  • 1044758-60-2